These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23841774)

  • 1. Author reply: To PMID 22372920.
    Tie J; Gibbs P
    Intern Med J; 2013 Jul; 43(7):844-5. PubMed ID: 23841774
    [No Abstract]   [Full Text] [Related]  

  • 2. Co-funded expanded access programmes for new oncology drugs: creating a two-tier system for Australian cancer patients?
    Azad A; Franco M
    Intern Med J; 2013 Jul; 43(7):843-4. PubMed ID: 23841773
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy.
    Woo J; Leighton JC
    Cancer; 2013 Dec; 119(24):4366-7. PubMed ID: 24108679
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab for resectable colorectal liver metastasis: new EPOC trial--author's reply.
    Primrose JN
    Lancet Oncol; 2014 Jul; 15(8):e306. PubMed ID: 24988933
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant therapy after hepatectomy for colorectal metastases.
    Fong Y
    Lancet Oncol; 2014 May; 15(6):544-5. PubMed ID: 24807857
    [No Abstract]   [Full Text] [Related]  

  • 6. Cetuximab for resectable colorectal liver metastasis: new EPOC trial.
    Hasegawa K; Oba M; Kokudo N
    Lancet Oncol; 2014 Jul; 15(8):e305-6. PubMed ID: 24988931
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials.
    Tie J; Gibbs P
    Intern Med J; 2013 Jan; 43(1):23-31. PubMed ID: 22372920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response phenotype as a predictive biomarker to guide treatment with targeted therapies.
    Oxnard GR; Schwartz LH
    J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750
    [No Abstract]   [Full Text] [Related]  

  • 9. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
    Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
    [No Abstract]   [Full Text] [Related]  

  • 10. Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani F; Cunningham D
    Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
    [No Abstract]   [Full Text] [Related]  

  • 11. When inoperable becomes operable?
    Mroczkowski P; Seidensticker M
    J Clin Oncol; 2013 Dec; 31(35):4474. PubMed ID: 24166527
    [No Abstract]   [Full Text] [Related]  

  • 12. Colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy.
    Hartman DJ; Chiosea SI
    Cancer; 2013 Dec; 119(24):4366. PubMed ID: 24113994
    [No Abstract]   [Full Text] [Related]  

  • 13. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
    Salazar R; Grasselli J; Santos C; Tabernero J
    Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
    [No Abstract]   [Full Text] [Related]  

  • 14. Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.
    Sunakawa Y; Takahashi T; Ichikawa W; Shimada K; Sasaki Y
    J Clin Oncol; 2013 Dec; 31(35):4473. PubMed ID: 24166514
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.
    Sarmiento R; Longo R; Gasparini G
    Int J Biol Markers; 2012 Dec; 27(4):e286-94. PubMed ID: 23280126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab proves active in wide range of cancers.
    Oncology (Williston Park); 2004 Aug; 18(9):1158, 1199. PubMed ID: 15471199
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J
    Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
    [No Abstract]   [Full Text] [Related]  

  • 18. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic colon cancer: "the times they are A-changing".
    Kemeny NE
    J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to S. Debska-Szmich et al.
    Van Cutsem E; Beier F; Ciardiello F
    J Clin Oncol; 2015 Oct; 33(30):3518. PubMed ID: 26304910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.